Navigation Links
Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in patients suffering from systemic sclerosis, a systemic fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152 is safe and well-tolerated at doses which are expected to provide a full range of receptor coverage in humans," said Isabelle DeArmond, Vice President, Clinical Development. "These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study in patients suffering from systemic sclerosis will be an important milestone for the team at Amira; we look forward to better understanding the potential therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at Amira.  Preclinical data has demonstrated that antagonism of the LPA1 receptor inhibits fibrosis in several disease models.  Much of these data has been previously presented and published by Amira scientists and colleagues.  Amira Pharmaceuticals also recently announced that AM152 was granted Orphan Drug Status by the FDA for patients suffering from idiopathic pulmonary fibrosis (IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
2. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
3. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
4. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. Visage Imaging Releases Amira 5.3
7. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
8. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
9. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
(Date:10/20/2014)... --  Mary,s Medicinals today announced that its 501(c)(3) ... of Operation Grow4Vets , a national, nonpartisan organization ... services to assist them in living with injuries sustained ... , An ever-increasing number of medical studies have ... for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain ...
(Date:10/19/2014)... DUBLIN , October 20, 2014 Shire ... James Bowling , Interim Chief Financial Officer (CFO), has notified the ... current role to pursue a new career opportunity as CFO of ... Q1 2015 and the company will commence a search for a ... commented: "James has helped build and lead a high-quality ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Conduct Conference Call on, December 10, 2007 to Discuss SNS-595 ... ... SOUTH SAN FRANCISCO, Calif., Nov. 29 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... announced that it,will present data on the company,s two lead product ...
... Raised Worldwide Awareness and Funds ... to Fight Aids, Tuberculosis and Malaria, SEATTLE, Nov. 28 ... and distributor, today announced,the successful conclusion of "Change Me," an ... their thoughts on how to make the,world a better place. ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology 3Getty Images Celebrates Conclusion of 'Change Me' Imagery Forum 2Getty Images Celebrates Conclusion of 'Change Me' Imagery Forum 3
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium organic ... to celebrate this month. October marks Italian Heritage Month – ... of Americans of Italian heritage and Italians in America. October ... its favorite Italian cocktails and encourages everyone to enjoy its ... it is only in a glass. , Punzoné continues ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... and increased weight in the middle school students reports that ... of food as motivation resulted in an increase in the ... and organizing fund raising programs with food as a sole ... two thirds of adults and on third of children population ...
... Evidence of brain enlargement has been discovered by magnetic ... suffer from autism, when in comparison to other normal ... ,Abnormalities in communication, repetitive and stereotyped behaviors, and ... The neuroanatomical basis for this condition is yet to ...
... Sexually Transmitted Infections in Africa (ICASA) aimed at combating ... the Continent’s scientists in Nigeria on 4 December 2005.// ... implementation of the projects and better utilization of funds. ... have been infected by the disease, which is representative ...
... vaccination against bird flu to all its poultry birds and wild ... to farmers and villagers about the importance of vaccination to poultry ... doubtful death of birds in their area as it is reported ... has reported two human deaths due to bird flu and is ...
... Washington it was reported that hormone injections (Leptin) taken twice daily ... weight. ,The research was headed by Dr Michael Rosenbaum ... // New York which shed light on the complex pathway that ... weight what is more difficult is to maintain the weight. ...
... University have found that increased levels of plasma lipoprotein ... increasing the risk of heart disease in these patients. ... the supporting tissue that surrounds the teeth. Previous studies ... diseases including diabetes and cardiovascular disease. The current study ...
Cached Medicine News:Health News:Leptin Injections Maintain Loss In Body Weight 2Health News:Severe Gum Disease Triples Heart Disease Risk 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: